PFE · NYSE
Pfizer (PFE) Stock Price & Fundamentals
Pfizer (PFE) closed at $471.02 on Oct 9, 2026, up 0.65% from the previous close of $467.96.
Share price, past year
1Y +21.76%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $471.02 |
| Sep 30, 2026 | $480.59 |
| Aug 31, 2026 | $478.18 |
| Jul 31, 2026 | $453.14 |
| Jun 30, 2026 | $453.62 |
| May 29, 2026 | $410.98 |
| Apr 30, 2026 | $413.95 |
| Mar 31, 2026 | $397.38 |
| Feb 27, 2026 | $365.11 |
| Jan 30, 2026 | $382.61 |
| Dec 31, 2025 | $371.56 |
| Nov 28, 2025 | $371.68 |
| Oct 31, 2025 | $389.87 |
Key statistics
- Market cap
- $2.68T
- P/E (TTM)
- 619.8
- EPS (TTM)
- $0.76
- Revenue (TTM)
- $63.70B
- Net income (TTM)
- $4.33B
- Shares outstanding
- 5.7B
- Dividend yield
- 0.37%
- 52-week range
- $357.88 – $487.42
Pfizer's market cap is $2.68T, based on a share price of $471.02 and 5.7B shares outstanding as of Jul 29, 2026.
Financials
Pfizer reported revenue of $62.58B for fiscal 2025, down 1.65% from fiscal 2024.
Pfizer earned net income of $7.77B in fiscal 2025, a net margin of 12.4%.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $62.58B | −1.7% | $7.77B | 12.4% | $1.36 | $9.08B |
| FY2024ended Dec 31, 2024 | $63.63B | +6.8% | $8.03B | 12.6% | $1.41 | $9.84B |
| FY2023ended Dec 31, 2023 | $59.55B | −41.1% | $2.12B | 3.6% | $0.37 | $4.79B |
| FY2022ended Dec 31, 2022 | $101.18B | +24.5% | $31.37B | 31.0% | $5.47 | $26.03B |
| FY2021ended Dec 31, 2021 | $81.29B | +95.2% | $21.98B | 27.0% | $3.85 | $29.87B |
| FY2020ended Dec 31, 2020 | $41.65B | +1.8% | $9.16B | 22.0% | $1.63 | $12.18B |
| FY2019ended Dec 31, 2019 | $40.91B | +0.2% | $16.03B | 39.2% | $2.82 | $10.54B |
| FY2018ended Dec 31, 2018 | $40.83B | −22.3% | $11.15B | 27.3% | $1.87 | $13.84B |
| FY2017ended Dec 31, 2017 | $52.55B | −0.5% | $21.31B | 40.6% | $3.52 | $14.85B |
| FY2016ended Dec 31, 2016 | $52.82B | — | $7.22B | 13.7% | $1.17 | $14.37B |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 28, 2026 | $15.03B | −$248.00M | −$0.04 |
| Q1 FY2026ended Mar 29, 2026 | $14.45B | $2.69B | $0.47 |
| Q4 FY2025ended Dec 31, 2025 | $17.56B | −$1.65B | −$0.29 |
| Q3 FY2025ended Sep 28, 2025 | $16.65B | $3.54B | $0.62 |
| Q2 FY2025ended Jun 29, 2025 | $14.65B | $2.91B | $0.51 |
| Q1 FY2025ended Mar 30, 2025 | $13.72B | $2.97B | $0.52 |
| Q4 FY2024ended Dec 31, 2024 | $17.76B | $410.00M | $0.07 |
| Q3 FY2024ended Sep 29, 2024 | $17.70B | $4.47B | $0.78 |
Company profile
- Name
- Pfizer, Inc.
- Ticker
- PFE
- Exchange
- NYSE
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 66 Hudson Boulevard East, New York, NY 10001-2192
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0000078003
Recent SEC filings
- Aug 4, 2026
- Aug 4, 2026
- Jun 18, 2026
- Jun 18, 2026
- May 5, 2026
- May 5, 2026
- Apr 27, 2026
- Feb 26, 2026
Frequently asked questions
What is Pfizer's stock price?
Pfizer (PFE) closed at $471.02 on Oct 9, 2026, up 0.65% from the previous close of $467.96.
What is Pfizer's market cap?
Pfizer's market cap is $2.68T, based on a share price of $471.02 and 5.7B shares outstanding as of Jul 29, 2026.
How much revenue does Pfizer make?
Pfizer reported revenue of $62.58B for fiscal 2025, down 1.65% from fiscal 2024.
What is PFE's P/E ratio?
Pfizer's price-to-earnings ratio is 619.8, based on trailing twelve-month diluted EPS of $0.76.
Does Pfizer pay a dividend?
Yes. Pfizer declared $1.72 per share in dividends over the last four quarters, a yield of 0.37%.
Sources and methodology
Fundamentals come from Pfizer, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures